4D Molecular Therapeutics Holds Annual Stockholder Meeting

Ticker: FDMT · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1650648

4d Molecular Therapeutics, INC. 8-K Filing Summary
FieldDetail
Company4d Molecular Therapeutics, INC. (FDMT)
Form Type8-K
Filed DateJun 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: stockholder-meeting, corporate-governance

TL;DR

4D Molecular Therapeutics stockholders met, voted on directors and auditors.

AI Summary

On June 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on several proposals, including the election of directors and the ratification of the appointment of its independent registered public accounting firm.

Why It Matters

This filing provides transparency on shareholder voting outcomes, which can indicate investor confidence and influence future corporate decisions.

Risk Assessment

Risk Level: low — This is a routine filing reporting on the results of an annual stockholder meeting, with no new material financial or operational information.

Key Players & Entities

FAQ

What was the primary purpose of the 8-K filing by 4D Molecular Therapeutics, Inc. on June 20, 2025?

The primary purpose was to report on the submission of matters to a vote of security holders, specifically the results of their annual meeting of stockholders held on June 17, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 17, 2025.

Where is 4D Molecular Therapeutics, Inc. incorporated?

4D Molecular Therapeutics, Inc. is incorporated in Delaware.

What is the business address of 4D Molecular Therapeutics, Inc. as listed in the filing?

The business address is 5858 Horton Street #455, Emeryville, California, 94608.

What is the IRS Employer Identification Number for 4D Molecular Therapeutics, Inc.?

The IRS Employer Identification Number is 47-3506994.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding 4D Molecular Therapeutics, Inc. (FDMT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing